HCMS

Generational Equity Advises Lobo Solutions in its Sale to HCMS Napa

Retrieved on: 
Wednesday, December 27, 2023

Generational Equity , a leading mergers and acquisitions advisor for privately held businesses, is pleased to announce the sale of its client Lobo Solutions, Inc. to HCMS Napa, LLC.

Key Points: 
  • Generational Equity , a leading mergers and acquisitions advisor for privately held businesses, is pleased to announce the sale of its client Lobo Solutions, Inc. to HCMS Napa, LLC.
  • Lobo Solutions (LSI), located in Poway, California, is a full-service provider of professional medical billing and coding services.
  • Located in Napa, California, HCMS Napa (HCMS) is a team of dedicated professionals specially trained to increase efficiency in medical billing and business systems.
  • “Ron Rosenow and Generational Equity were excellent to work with during this sale transaction,” said Kenneth Lobo, Founder and Owner of Lobo Solutions.

Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, November 8, 2023

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today reported financial results and provided a corporate update for the third quarter ended September 30, 2023.

Key Points: 
  • In October 2023, Tenaya shared positive Phase 1 data for TN-301 at the 2023 Heart Failure Society of America (HFSA) Annual Scientific Meeting.
  • General & Administrative (G&A) Expenses: G&A expenses for the quarter ended September 30, 2023, were $7.8 million.
  • Non-cash stock-based compensation included in G&A expense was $2.2 million for the quarter ended September 30, 2023.
  • Net Loss: Net loss for the quarter ended September 30, 2023, was $29.1 million, or $0.39 per share.

Cytokinetics Announces Upcoming Presentations at the 2023 HCMS Scientific Sessions and the HFSA Annual Scientific Meeting

Retrieved on: 
Monday, October 2, 2023

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), today announced upcoming presentations at the 2023 Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions on October 6, 2023, and at the Heart Failure Society of America (HFSA) Annual Scientific Meeting, taking place from October 6-9, 2023, both taking place in Cleveland, OH.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), today announced upcoming presentations at the 2023 Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions on October 6, 2023, and at the Heart Failure Society of America (HFSA) Annual Scientific Meeting, taking place from October 6-9, 2023, both taking place in Cleveland, OH.
  • Title: Baseline Characteristics of Patients in SEQUOIA-HCM: A Phase 3 Trial of Aficamten in Obstructive Hypertrophic Cardiomyopathy
    Title: Cardiovascular Hospitalizations Post Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy: A 3-year Analysis of 5,101 Patients

Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences

Retrieved on: 
Thursday, September 21, 2023

SOUTH SAN FRANCISCO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced today that poster presentations related to its TN-201 and TN-301 programs will be presented at the 2023 Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions taking place October 6, 2023, and at the Heart Failure Society of America (HFSA) Annual Scientific Meeting occurring October 6-9, 2023. Both meetings are being held this year in Cleveland, Ohio.

Key Points: 
  • TN-301 is Tenaya’s proprietary, highly selective small molecule inhibitor of histone deacetylase 6 (HDAC6) being developed for the potential treatment of heart failure with preserved ejection fraction (HFpEF).
  • Data to be presented at HFSA will include results from the company’s Phase 1 clinical trial of TN-301 in healthy adult participants.
  • Tenaya has previously reported that TN-301 was generally well tolerated and that target engagement was achieved.
  • The company will also present new data from preclinical studies examining the effects of its HDAC6 inhibitor in combination with an approved HFpEF treatment in a model of disease.

Anna Dadosky Joins Houston Community Management Services As Business Development Manager

Retrieved on: 
Thursday, April 13, 2023

HOUSTON, April 13, 2023 (GLOBE NEWSWIRE) -- Associa Houston Community Management Services (HCMS) , a leading provider of community management services throughout the greater Houston, League City, and Sugarland areas, is pleased to announce that Anna Dadoksy has joined the company as business development manager.

Key Points: 
  • HOUSTON, April 13, 2023 (GLOBE NEWSWIRE) -- Associa Houston Community Management Services (HCMS) , a leading provider of community management services throughout the greater Houston, League City, and Sugarland areas, is pleased to announce that Anna Dadoksy has joined the company as business development manager.
  • In this capacity, she will work with business development staff and branch leadership to bring Associa’s comprehensive range of value-added services to new and existing clients supported by the company throughout southeast Texas.
  • Dadoksy joined HCMS in 2020 with a strong background in all facets of management and team leadership.
  • Dadosky brings strong expertise in board member relations, budgeting and finances, project management, vendor negotiation, and oversight.

Associa Promotes Erica Slater To Regional Sales Director

Retrieved on: 
Thursday, January 12, 2023

DALLAS, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Associa , the community management industry’s largest company, is pleased to announce that Erica Slater, CMCA®, has accepted the role of regional sales director for its Central and Canadian regions.

Key Points: 
  • DALLAS, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Associa , the community management industry’s largest company, is pleased to announce that Erica Slater, CMCA®, has accepted the role of regional sales director for its Central and Canadian regions.
  • Slater most recently served as business development manager with Associa Houston Community Management Services (HCMS).
  • In 2021, Slater was a member of the Associa Sales Team of the Year, and in 2022, she single-handedly generated more than $450,000 in annual management fees for HCMS.
  • “Erica has seen tremendous success in every phase of her career with Associa,” said Leslie Baldwin, Associa vice president of sales.

Health Care Management Solutions Data Breach Alert: Issued by Wolf Haldenstein Adler Freeman & Herz LLP

Retrieved on: 
Friday, December 16, 2022

NEW YORK and CHICAGO, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP, a preeminent national consumer right law firm, is investigating claims on behalf of customers Health Care Management Solutions (“HCMS”), a Medicare/Medicaid subcontractor, whose information may be have stolen in a recent data breach.

Key Points: 
  • NEW YORK and CHICAGO, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP, a preeminent national consumer right law firm, is investigating claims on behalf of customers Health Care Management Solutions (“HCMS”), a Medicare/Medicaid subcontractor, whose information may be have stolen in a recent data breach.
  • Wolf Haldenstein Adler Freeman & Herz LLP has extensive experience in the prosecution of consumer rights litigation in state and federal trial and appellate courts across the country.
  • The firm has attorneys in various practice areas and offices in New York, Chicago and San Diego.
  • Courts have repeatedly recognized the reputation and expertise of this firm and have appointed it to major positions in complex consolidated litigation.

Tracy Downs Promoted To President Of Operations

Retrieved on: 
Monday, October 17, 2022

Downs joined HCMS in 2001 and has worked in a number of accounting, operations, project planning, and client support roles.

Key Points: 
  • Downs joined HCMS in 2001 and has worked in a number of accounting, operations, project planning, and client support roles.
  • In her 20+ year career with Associa, she has served as accounts payable clerk, accounting supervisor, director of operations, and branch vice president prior to her promotion to branch president.
  • Based on her prior experience, Downs brings a valuable combination of accounting and operations expertise to her new role.
  • Tracy Downs is a wonderful example of the industry-leading career opportunities and professional growth Associa offers its employees, said Associa Regional Vice President Shawn Fazekas, CMCA.

Tenaya Therapeutics to Participate in Inaugural Hypertrophic Cardiomyopathy Medical Society’s 2022 Scientific Sessions

Retrieved on: 
Thursday, September 29, 2022

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced today that it is scheduled to participate in the Hypertrophic Cardiomyopathy Medical Societys (HCMS) inaugural 2022 Scientific Sessions taking place September 30, 2022, virtually and in National Harbor, MD.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced today that it is scheduled to participate in the Hypertrophic Cardiomyopathy Medical Societys (HCMS) inaugural 2022 Scientific Sessions taking place September 30, 2022, virtually and in National Harbor, MD.
  • Whit Tingley, M.D., Ph.D., Tenayas Chief Medical Officer, will join an industry panel to discuss advances in genetic therapies and its potential in individuals with HCM.
  • Details of Tenayas participation are as follows:
    The HCMS Sessions are intended to highlight the history, major developments and emerging concepts in hypertrophic cardiomyopathy (HCM), including learning about genetic forms of HCM and emerging treatments.
  • TN-201 is an adeno-associated virus-based gene therapy being developed to treat hypertrophic cardiomyopathy (HCM) due to disease-causing variants in the Myosin Binding Protein C3 (MYBPC3) gene.

Taos’ New Hybrid Cloud Managed Service Delivers Centralized, Unified View of Infrastructure Resources

Retrieved on: 
Tuesday, May 10, 2022

To help in this effort, Taos now provides the Hybrid Cloud Managed Service (HCMS), which monitors an enterprises heterogeneous infrastructure resources, providing a central unified view.

Key Points: 
  • To help in this effort, Taos now provides the Hybrid Cloud Managed Service (HCMS), which monitors an enterprises heterogeneous infrastructure resources, providing a central unified view.
  • Hybrid Cloud Managed Service is designed for organizations looking to reduce IT operations burden on their internal teams through 24x7 monitoring, alerting, and troubleshooting for both on-premises and cloud workloads.
  • The service is offered through two main models:
    In the Shared Service Model, the Taos team focuses on maintenance, monitoring, networks, databases, and support solutions.
  • Taos helps todays enterprises and rapidly growing businesses harness the power of the cloud and DevOps with digital transformation and optimization solutions.